nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Company profile
Ticker
NYMXF
Exchange
Website
CEO
Paul Averback
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NYMXF stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
28 Mar 24
6-K
Current report (foreign)
15 Nov 23
6-K
Current report (foreign)
9 Nov 23
6-K
Current report (foreign)
6 Nov 23
6-K
Current report (foreign)
26 Oct 23
6-K
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
25 Sep 23
25-NSE
Exchange delisting
8 Sep 23
6-K
Nymox Reports Completion of $2 Million Private Placement
29 Aug 23
6-K
Current report (foreign)
14 Aug 23
6-K
Nymox Announces $2 Million Private Placement
2 Aug 23
Latest ownership filings
4/A
James George Robinson
26 Jun 23
4/A
James George Robinson
18 May 23
4
James George Robinson
6 May 22
4
James George Robinson
27 Apr 21
4
James George Robinson
12 Jul 19
4
James George Robinson
10 Jul 19
4
James George Robinson
9 Jul 19
4
James George Robinson
3 Jul 19
4
James George Robinson
2 Jul 19
4
James George Robinson
1 Jul 19
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Apr 23 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 0.47 | 40,000 | 18.80 k | 4,782,065 |
25 Apr 23 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 0.45 | 40,000 | 18.00 k | 4,742,065 |
25 Apr 23 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 0.45 | 40,000 | 18.00 k | 4,742,065 |